title: Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial.
authors.forename: Alireza
authors.initials: A
authors.lastname: Firooz
authors.forename: Amirreza
authors.initials: A
authors.lastname: Solhpour
authors.forename: Farzam
authors.initials: F
authors.lastname: Gorouhi
authors.forename: Maryam
authors.initials: M
authors.lastname: Daneshpazhooh
authors.forename: Kamran
authors.initials: K
authors.lastname: Balighi
authors.forename: Khalil
authors.initials: K
authors.lastname: Farsinejad
authors.forename: Mehdi
authors.initials: M
authors.lastname: Rashighi-Firoozabadi
authors.forename: Yahya
authors.initials: Y
authors.lastname: Dowlati
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D065095:Calcineurin Inhibitors; D012628:Dermatitis, Seborrheic / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005148:Facial Dermatoses / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D019696:Peptidylprolyl Isomerase / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; C021650:hydrocortisone acetate; C117268:pimecrolimus; D019696:Peptidylprolyl Isomerase; D006854:Hydrocortisone; D016559:Tacrolimus